NCT05803499

Brief Summary

The purpose of this study is to develop and optimize a targeted behavioral intervention for sleep disturbance among individuals who have recently lost a spouse/long-term cohabitating partner. In the first phase of this study, patient focus groups were conducted to gather information about the unique sleep challenges experienced by spousally bereaved individuals and the kinds of support they would like to receive from a program based on Cognitive Behavior Therapy for Insomnia (CBT-I). In the second phase of the study, a two-arm randomized controlled trial will be conducted to compare changes in sleep and inflammation among participants in the targeted CBT-I intervention to those in an information-only control. Participants will be asked to attend two in-person visits (at baseline and, approx. 8 weeks later, at post-treatment) to provide a blood sample and have vital signs and basic anthropometric measurements (height, weight, waist circumference) taken. After their baseline visit, participants will be randomized into either the targeted CBT-I intervention or the information-only control. The targeted CBT-I intervention will entail 6 online sessions (approx. 50 mins. each) delivered via videoconference by a trained facilitator, once per week over the course of approx. 6 weeks. The information-only control will entail 1 online session (approx. 50 mins.) delivered via videoconference by a trained facilitator. Sleep data (collected via both actigraphy watches and patient self-report sleep diaries) and data on mood, grief, and sleep habits will be collected from participants at three timepoints (baseline, post-treatment, and then again at a 6-month follow-up).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 21, 2023

Completed
8 days until next milestone

Study Start

First participant enrolled

March 1, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 7, 2023

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2025

Completed
Last Updated

January 21, 2026

Status Verified

January 1, 2026

Enrollment Period

2.5 years

First QC Date

February 21, 2023

Last Update Submit

January 20, 2026

Conditions

Keywords

sleep disturbanceinflammationquality of lifebereavementspouses

Outcome Measures

Primary Outcomes (8)

  • Feasibility of recruitment

    Feasibility of recruitment will be demonstrated by an enrollment benchmark of 2 participants per month.

    Approximately 18 months

  • Feasibility of recruitment

    Feasibility of recruitment will also be measured by the proportion of eligible participants who are enrolled (consented) and randomized.

    Approx. 18 months

  • Adherence to the intervention

    Adherence to the intervention will be measured by the number of sessions attended by participants.

    Approx. 6 months

  • Treatment-specific retention rates

    Treatment-specific retention will be measured by the percentage of participants who complete the post-treatment assessment in each arm.

    Approx. 6 months

  • Acceptability

    The acceptability of the intervention will be demonstrated by ≥ 85% completion of the study protocol across the sample.

    Approx. 6 months

  • Attrition

    Attrition will be measured at each follow-up visit (post intervention and 6-month follow-up) and will be defined by the percentage of randomized participants who did not attend the follow-up visit. Causes of attrition will be measured by analyzing reasons for participant drop-out as documented over the course of the study.

    Approx. 6 months

  • Treatment-specific acceptability

    Treatment-specific acceptability will be measured by preference ratings gathered during the post-treatment debriefing session for each arm.

    Approx. 6 months

  • Preliminary change in sleep disturbance

    Using the previously validated Pittsburgh Sleep Quality Index (PSQI), change in sleep disturbance will be assessed from baseline to 1. post-intervention (6-8 weeks later), and a 2. six-month follow-up. Global scores on the PSQI range from 0 to 21, with a higher score indicating more severe sleep disturbance.

    Approx. 6 months

Secondary Outcomes (2)

  • Preliminary change in inflammation

    Approx. 8 weeks

  • Preliminary change in quality of life

    Approx. 6 months

Study Arms (2)

Targeted Intervention for Sleep and Bereavement (Targeted CBT-I)

EXPERIMENTAL

This intervention consists of 6, 50-60-minute online individual sessions delivered via video conference. Content will include a CBT-I based program adapted to the specific needs of spousally bereaved individuals.

Behavioral: Targeted Cognitive Behavior Therapy for Insomnia

Information-Only Control

PLACEBO COMPARATOR

The information-only control consists of 1, 50-60-minute online individual session delivered via video conference. Content will provide basic psychoeducation about sleep and aging.

Other: Information-Only Control

Interventions

This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.

Targeted Intervention for Sleep and Bereavement (Targeted CBT-I)

The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.

Information-Only Control

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • Has experienced the loss of a spouse/long-term cohabitating partner (i.e., partner who lived with participant for at least 1 year before passing) within the past 3 months
  • Scores 5 or above on the Pittsburgh Sleep Quality Inventory (PSQI; administered by research staff during phone screening call)
  • Must have access to an internet-enabled device (e.g., smartphone, computer, tablet) to take part in the online intervention

You may not qualify if:

  • Under age 18
  • Non-English speakers
  • Those with a previously diagnosed sleep disorder (e.g., restless leg syndrome; note: individuals with obstructive sleep apnea (OSA) will be eligible as long as they use a continuous positive airway pressure (CPAP) machine at least 5 days a week for at least 5 hours per day)
  • Those who have been taking prescribed sleep medication(s) for 6 months or more
  • Those with autoimmune or inflammatory diseases (such as: acute or chronic immune system medical conditions, medications or other conditions that impact immune function (e.g., chronic fatigue syndrome \[CFS\], lupus, rheumatoid arthritis, Sjogren's disease, systemic lupus erythematosus \[SLE\], Hepatitis C, or any other immunosuppressive treatment requiring conditions, per investigator discretion).
  • Those who regularly use illegal substances.
  • Those who are on medications with major immunological consequences (e.g. steroids)
  • Women who are pregnant or nursing
  • Those who have been vaccinated in the past two weeks (note: these individuals may simply delay enrollment by two weeks if otherwise eligible)
  • Those with significant visual or auditory impairment, medical or psychiatric condition that is unstable, requires immediate treatment or is judged to interfere with study protocol (e.g., substance abuse, psychotic disorder, cognitive disorder, current suicidal ideation)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern University Feinberg School of Medicine

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

ParasomniasInflammation

Condition Hierarchy (Ancestors)

Sleep Wake DisordersNervous System DiseasesMental DisordersPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Participants will not be informed which arm they have been randomized into. Research assistants will also be blinded to randomization. Only the control and intervention session facilitators and Principal Investigator will be aware of participants' study arm.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This pilot will test the targeted intervention for feasibility, acceptability, and preliminary effects. Participants will be randomized to either 1) the targeted intervention for bereavement and sleep disturbance based on Cognitive Behavior Therapy for Insomnia (CBT-I), and 2) an information-only control. Participants will complete self-report measures and an in-person visit at baseline and post-treatment, and a 6-month follow-up (psychosocial measures only).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Preventive Medicine (Epidemiology)

Study Record Dates

First Submitted

February 21, 2023

First Posted

April 7, 2023

Study Start

March 1, 2023

Primary Completion

August 31, 2025

Study Completion

August 31, 2025

Last Updated

January 21, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the primary results of the trial after deidentification will be shared.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
Beginning 9 months and ending 36 months following publication of the primary results.
Access Criteria
Data will be available for individual participant data meta-analysis. Proposals may be submitted up to 36 months following publication of the primary results and should be directed to diana.chirinos@northwestern.edu.

Locations